Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

Abayasingam, Arunasingam; Balachandran, Harikrishnan; Agapiou, David; Hammoud, Mohamed; Rodrigo, Chaturaka; Keoshkerian, Elizabeth; Li, Hui; Brasher, Nicholas A.; Christ, Daniel; Rouet, Romain; Burnet, Deborah L.; Grubor‐Bauk, Branka; Rawlinson, William D.; Turville, Stuart; Aggarwal, Anupriya; Stella, Alberto Ospina; Fichter, Christina; Brilot, Fabienne; Mina, Michael; Post, Jeffrey J.; Hudson, Bernard; Gilroy, Nicky; Dwyer, Dominic E.; Sasson, Sarah C.; Charabati, Marc; Pilli, Deepti; Kelleher, Anthony D.; Tedla, Nicodemus; Lloyd, Andrew R.; Martinello, Marianne; Bull, Rowena A.

doi:10.1016/j.xcrm.2021.100228

Cited by 72 publications

(95 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous acute phase studies showed that COVID-19 severity was associated with higher antibody responses. Here, hospitalization was associated with higher immunoglobulin levels many months after convalescence, suggesting that severity does not affect stability of memory B cell and plasma cells producing antibodies [ 2 – 4 , 19 ]. Common symptoms like fever and highly specific symptoms like alteration in smell and taste were also associated with higher antibodies.…”

Section: Resultsmentioning

confidence: 99%

“…Diversity in epitope specificity, quality, and functional capacity of antibodies will likely affect the efficacy of the immunity mediated. Antibodies elicited after exposure to SARS-CoV-2 have been associated with protective immunity up to 6 months [ 2 – 5 ], although we do not yet have a correlate of protection, and reinfections occur seemingly at a low frequency. The spike (S) protein on the virus surface is considered the main target of protective antibodies and the component of the leading vaccines [ 6 ] already under implementation.…”

Section: Introductionmentioning

confidence: 89%

See 1 more Smart Citation

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

Dobaño

Ramírez‐Morros

Alonso

et al. 2021

BMC Med

View full text Add to dashboard Cite

We assessed the duration and baseline determinants of antibody responses to SARS-CoV-2 spike antigens and the occurrence of reinfections in a prospective cohort of 173 Spanish primary health care worker patients followed initially for 9 months and subsequently up to 12.5 months after COVID-19 symptoms onset. Seropositivity to SARS-CoV-2 spike and receptor-binding domain antigens up to 149–270 days was 92.49% (90.17% IgG, 76.3% IgA, 60.69% IgM). In a subset of 64 health care workers who had not yet been vaccinated by April 2021, seropositivity was 96.88% (95.31% IgG, 82.81% IgA) up to 322–379 days post symptoms onset. Four suspected reinfections were detected by passive case detection, two among seronegative individuals (5 and 7 months after the first episode), and one low antibody responder. Antibody levels significantly correlated with fever, hospitalization, anosmia/hypogeusia, allergies, smoking, and occupation. Stable sustainment of IgG responses raises hope for long-lasting COVID-19 vaccine immunity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 89%

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

Dobaño

Ramírez‐Morros

Alonso

et al. 2021

BMC Med

View full text Add to dashboard Cite

show abstract

“…Spike-specific IgG antibodies and virus-specific memory T cells may decrease with time, but virus-specific memory B-cells increase. 12…”

Section: Figurementioning

confidence: 99%

Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals

Sapkal

Yadav

Sahay

et al. 2021

Preprint

View full text Add to dashboard Cite

The recent emergence of B.1.617 lineage has created grave public health problem in India. The lineage further mutated to generate sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3. Apparently, the Delta variant has slowly dominated the other variants including B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3. With this, World Health Organization has described this sub-lineage as variant of concern. The high transmissibility associated with Delta variant has led to second wave of pandemic in India which affected millions of people. Besides this, variant of concerns has been reported to show lower neutralization to several approved vaccines. This has led to breakthrough infections after completion of vaccination regimen. There is limited information available on the duration of protective immune response post-infection, vaccination or breakthrough infection with SARS-CoV-2. In this study, we have evaluated immune response in sera of the Covishield vaccinated individuals belonging to category: I. one dose vaccinated, II. two doses vaccinated, III. COVID-19 recovered plus one dose vaccinated, IV. COVID-19 recovered plus two doses vaccinated and V. breakthrough COVID-19 cases. The findings of the study demonstrated that the breakthrough cases and the COVID-19 recovered individuals with one or two dose of vaccine had relatively higher protection against Delta variant in comparison to the participants who were administered either one or two doses of Covishield. Prior vaccination results in less severe disease against subsequent infection provide evidence that both humoral and cellular immune response play an important role in protection.

show abstract

“…A recent study confirmed that SARS-CoV-2 infection induces long-lived bone marrow plasma cells [493]. Thus, waning nAb titers in plasma several months post infection may be compensated by the persistent Bmem repertoire that remains at constant levels or can even increase [494]. Further studies are required to elucidate the contribution and protective capacity of Bmem cells in SARS-CoV-2 infection.…”

Section: B Cellsmentioning

confidence: 91%

SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise

Duerr¹,

Jimenez²,

Dittmann³

2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 and HIV are zoonotic viruses that rapidly reached pandemic scale causing global losses and fear. The COVID-19 and AIDS pandemics ignited massive efforts worldwide to develop antiviral strategies and characterize viral architectures, biological and immunological properties, and clinical outcomes. Although both viruses have a comparable appearance as enveloped viruses with positive-stranded RNA and envelope spikes mediating cellular entry, the entry process, downstream biological and immunological pathways, clinical outcomes, and disease courses are strikingly different. This review provides a systemic comparison of both viruses’ structural and functional characteristics delineating their distinct strategies for efficient spread.

show abstract

Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

Cited by 72 publications

References 46 publications

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals

SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise

Contact Info

Product

Resources

About